Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

Company Calls Off Inhaled Remdesivir Program

Executive Summary

HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.

You may also be interested in...



Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention

Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial. 

Gilead Teases Big Cancer Drug Readouts In Second Half

The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.

Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel